CE Disclosures and Faculty Information

• OVERVIEW OF ACTIVITY
  
  Management of ovarian cancer (OC) includes optimal surgical debulking followed by postoperative chemotherapy and, in most cases, subsequent medical management when the disease recurs. Although many single-agent and combination chemotherapy regimens have been studied, only recently have antibody and small-molecule growth-inhibitory targeted agents been integrated into the OC research milieu. It is hoped that the results from these trials will lead to the emergence of new therapeutic agents and changes or enhancements in the indications for existing treatment strategies, ultimately improving the duration and quality of life for patients with metastatic OC. To bridge the gap between research and patient care, this issue of Ovarian Cancer Update features one-on-one discussions with leading gynecologic oncology investigators. By providing information on the latest research developments, this activity attempts to assist medical and gynecologic oncologists with the formulation of therapeutic strategies, which in turn facilitates optimal patient care.
  
  LEARNING OBJECTIVES

  • Use case-based learning to develop individualized management strategies for optimally debulked Stage II to III OC, including the use of intraperitoneal versus intravenous chemotherapy.
  • Consider emerging data focused on the use of angiogenesis inhibition when designing front-line and maintenance therapeutic strategies for patients with OC.
  • Develop an evidence-based algorithm for the systemic treatment of recurrent platinum-sensitive and platinum-resistant OC, including the option of anti-angiogenic therapy alone or in combination with chemotherapy.
  • Offer BRCA testing to appropriately selected patients with OC to better facilitate discussions about prognosis, optimal treatment selection and the option of clinical trial participation with promising novel agents.
  • Develop an algorithm for the use of CA125 surveillance to monitor patients for relapsed OC.
  • Recall the rationale for and activity of novel targeted agents under investigation for the treatment of OC.
  • Counsel appropriately selected patients with OC about the availability of and participation in ongoing clinical trials.
  ACCREDITATION STATEMENT
  
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CME credit is no longer available for this issue
  
  CREDIT DESIGNATION STATEMENT
  
  CME credit is no longer available for this issue
  
  HOW TO USE THIS CME ACTIVITY
  
  CME credit is no longer available for this issue
  
  This CME activity contains an audio component. The participant should listen to the audio MP3s.
  
  CONTENT VALIDATION AND DISCLOSURES
  
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr Karlan — Paid Research: Abbott Laboratories, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Genentech BioOncology. Dr Markman — Advisory Committee: Amgen Inc, Boehringer Ingelheim Pharmaceuticals Inc, Celgene Corporation, Eisai Inc, Genentech BioOncology, Hana Biosciences Inc, Sanofi; Speakers Bureau: Lilly USA LLC. Dr Penson — Data Safety and Monitoring Committee Chair: Genentech BioOncology; Paid Research: Amgen Inc, AstraZeneca Pharmaceuticals LP, Eisai Inc, Endocyte Inc, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company. Dr Secord — Advisory Committee: Boehringer Ingelheim Pharmaceuticals Inc, Lilly USA LLC, Pfizer Inc; Paid Research: Bristol-Myers Squibb Company, Eisai Inc, GlaxoSmithKline, Lilly USA LLC, Sanofi; Speakers Bureau: Lilly USA LLC.
  
  EDITOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Allos Therapeutics, Amgen Inc, Astellas Pharma Global Development Inc, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Cephalon Inc, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Genentech BioOncology, Genomic Health Inc, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Lilly USA LLC, Millennium: The Takeda Oncology Company, Mundipharma International Limited, Myriad Genetics Inc, Novartis Pharmaceuticals Corporation, OSI Oncology, Sanofi and Seattle Genetics.
  
  RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from Amgen Inc, Boehringer Ingelheim Pharmaceuticals Inc and Genentech BioOncology.
  
  Hardware/Software Requirements:
  An Internet connection that is at least 28.8 Kbps
  A monitor set to 1280 x 1024 pixels or more
  Internet Explorer 6.x or newer, Firefox 2.x or newer, or Safari 2.x or newer
  Macromedia Flash plug-in 6.0 or greater
  Adobe Acrobat Reader
  (Optional) Sound card and speakers for audio
  
  Last review date: October 2011
  Expiration date: October 2012